Calan (Verapamil HCI) Cardiovascular agent Calcium channel blocking agent 1) Management of Prinzmetal's or variant angina or unstable or chronic, stable angina pectoris; 2) Supraventricular tachyarrhythmias; 3) Prevention of recurrent paroxysmal supraventricular tachycardia; 4) Hypertension. Individualize. Max 480mg/day. Angina: 80 to 120mg 3 times daily before or after meal. Category C Constipation, dizziness, nausea, Low Blood Pressure, slow heart beats, headache, fatigue, peripheral edema, transient hypotension. Pregnancy Risk Categories defined: A: Studies in pregnant women failed to show a risk to the fetus in the first trimester - with no evidence of risk in the later trimesters. B: Animals studies indicate no adverse effect to the fetus, but there are no adequate, clinical studies in pregnant women. C: Animal studies have shown an adverse effect on the fetus, but there are no adequate, clinical studies in humans. Despite potential risks, the drug may be useful in pregnant women. D: There is evidence of risk to the human fetus, but the potential benefits of use in pregnant women may be acceptable, despite potential risks. X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any potential benefit from using the drug in pregnant women, regardless of trimester. NR: Not rated (i.e., no information available at this time as to the potential risks or benefits).